Found vs IVIM Health vs ShedRx (2026)

On tirzepatide, the order is IVIM Health↗ ($278) → ShedRx↗ ($289) → Found ($289) — gaps of $11 and then $0 a month, a $132 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

IVIM Health: the record, condensed

Start with the load-bearing figure: $278 a month, all-in, is what IVIM Health charges for tirzepatide at the 10 mg basis. The structure is tiered: the advertised entry point is $208, but the maintenance figure — the one a full year is actually billed at — is $278. That $70 gap between the ad and the anniversary is the single most important line in this record.

The all-in figure already contains a compulsory $75 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $203 would be exactly that kind of mirage.

To place the number: #3 of 17 verified programs, with the floor $63/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $171 a month. A year at this figure: $3,336 monthly-billed.

Start with the load-bearing figure: $149 a month, all-in, is what IVIM Health charges for semaglutide at the 2.4 mg basis. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.

A required $75/month membership is part of the deal, and part of the figure above: $74 of medication plus $75 of platform equals the $149 that leaves your account. Judge the membership by what it includes, but compare on the total.

Context for that figure: it ranks #3 of 20 in the verified semaglutide index — $16/month above the floor (Oak Longevity, $133) — and sits $200 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $1,788.

Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗

ShedRx: the record, condensed

ShedRx’s tirzepatide program bills $289 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Note the shape: $199 is the number in the marketing, $289 is the number at maintenance. The $90 difference is not a fee or a trick per se — it is dose-tiered pricing doing what dose-tiered pricing does — but it means the advertised figure describes month one, not month twelve.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes ShedRx unusually easy to compare and unusually easy to leave.

To place the number: #5 of 17 verified programs, with the floor $74/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

ShedRx’s semaglutide program bills $249 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The structure is tiered: the advertised entry point is $175, but the maintenance figure — the one a full year is actually billed at — is $249. That $74 gap between the ad and the anniversary is the single most important line in this record.

There is no membership line. $249 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #13 of 20 in the verified semaglutide index — $116/month above the floor (Oak Longevity, $133) — and sits $100 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,988.

Operationally at ShedRx: shipping included; commitment none month-to-month; cancellation 72-hour notice before the next billing cycle; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the ShedRx page · visit ShedRx ↗

Found: the record, condensed

On tirzepatide, the number that matters at Found is $289 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes Found unusually easy to compare and unusually easy to leave.

To place the number: #6 of 17 verified programs, with the floor $74/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

On semaglutide, the number that matters at Found is $289 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #15 of 20 in the verified semaglutide index — $156/month above the floor (Oak Longevity, $133) — and sits $60 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,468.

Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗

§ The three-way read

Prices, gaps, and what sits inside them

IVIM Health holds the low ground at $278 (its $75 membership already inside). ShedRx follows at $289 (+$11/mo, $132/yr). Found tops the trio at $289 (+$11/mo over the leader, $132/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: IVIM Health $149 → ShedRx $249 → Found $289 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: IVIM Health ($278); cheapest 12-month path: IVIM Health ($3,336); simplest billing (no membership): ShedRx and Found; dose-flat structure: Found; cheapest semaglutide of the three: IVIM Health ($149).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: IVIM Health vs ShedRx · IVIM Health vs Found · ShedRx vs Found.

§ Structure, three ways

Everything besides the three prices

Memberships: IVIM Health $75/mo (inside its figure); ShedRx none; Found none. Structures: IVIM Health step/tiered; ShedRx step/tiered; Found dose-flat. Pharmacies: IVIM Health not named; ShedRx not named; Found not named. States: IVIM Health — not published; ShedRx — not published; Found — most states. Exit terms: IVIM Health — membership mandatory; ShedRx — 72-hour notice before the next billing cycle; Found — membership recurs; prepaid terms are paid up front.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: IVIM Health source-verified (2026-08-05); ShedRx source-verified (2026-08-05); Found third-party reported (2026-08-05).

The trio on semaglutide, across time

3 mo: IVIM Health $447 vs ShedRx $747 vs Found $867 6 mo: IVIM Health $894 vs ShedRx $1,494 vs Found $1,734 12 mo: IVIM Health $1,788 vs ShedRx $2,988 vs Found $3,468 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

IVIM Health: $3,336/yr monthly-billed; ShedRx: $3,468/yr monthly-billed; Found: $3,468/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $264 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

A three-way choice is really two eliminations, so run them in order. Eliminate Found first unless it names its edge: at $289 it carries a $11/month premium over the floor of this trio — $132 a year, about 0.5 extra months of therapy at IVIM Health’s rate — and a premium that size must point at a specific line in its record (its insurance navigation) or it is decoration. Then interrogate ShedRx’s middle ground: nothing structural — its case is purely situational; if that specific thing is on your personal ledger, the $11/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is IVIM Health at $278, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.

The same trio on best published rate: IVIM Health $278 → ShedRx $289 → Found $289 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — IVIM Health $834, ShedRx $867, Found $867; 6 months — IVIM Health $1,668, ShedRx $1,734, Found $1,734. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): IVIM Health 4/5, ShedRx 4/5, Found 3/5. IVIM Health discloses the most and Found the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. The three match on every disclosure axis, which is rare and worth noting in their favor collectively. Scores recompute from the public records like everything else here.

Read as a decision: start from IVIM Health and make the other two argue upward. ShedRx’s case is its structure; Found’s case must be worth $132 a year in named features — the honest unit being months of medication (0.5 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.